Ibrutinib manufacturer is classified as a Bruton's tyrosine kinase (BTK) inhibitor. It works by blocking an enzyme (BTK) that cancer cells need to survive and multiply. By inhibiting this enzyme, ibrutinib can stop the growth of cancerous cells, helping to manage or even shrink tumors.
The drug is considered revolutionary for blood cancers because, unlike traditional chemotherapy, it is taken orally and generally causes fewer side effects. This is particularly beneficial for patients who need long-term treatment, as it allows them to continue their therapy with minimal disruption to their daily lives.
Reparation de toitures, In